P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects

Rimegepant (Nurtec ODT)—an orally administered, small‐molecule calcitonin gene–related peptide receptor antagonist indicated for the acute and preventive treatment of migraine—is a substrate for both the P‐glycoprotein and breast cancer resistance protein transporters in vitro. We evaluated the effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhardwaj, Rajinder, Collins, Julie L., Stringfellow, Joseph, Madonia, Jennifer, Anderson, Matt S., Finley, Jeri‐anne, Stock, David A., Coric, Vladimir, Croop, Robert, Bertz, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311059/
https://www.ncbi.nlm.nih.gov/pubmed/35304977
http://dx.doi.org/10.1002/cpdd.1088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311059/
https://www.ncbi.nlm.nih.gov/pubmed/35304977
http://dx.doi.org/10.1002/cpdd.1088

Ejemplares similares